MLYS
Price
$38.90
Change
-$0.30 (-0.77%)
Updated
Dec 4, 04:59 PM (EDT)
Capitalization
3.1B
Intraday BUY SELL Signals
NEVPF
Price
Loading...
Change
-$0.00 (-0.00%)
Updated
Loading...
Capitalization
45.13M
Intraday BUY SELL Signals
Interact to see
Advertisement

MLYS vs NEVPF

Header iconMLYS vs NEVPF Comparison
Open Charts MLYS vs NEVPFBanner chart's image
Mineralys Therapeutics
Price$38.90
Change-$0.30 (-0.77%)
Volume$58.61K
Capitalization3.1B
Abliva AB
PriceLoading...
Change-$0.00 (-0.00%)
Volume$58.9K
Capitalization45.13M
MLYS vs NEVPF Comparison Chart in %
MLYS
Daily Signal:
Gain/Loss:
NEVPF
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
MLYS vs. NEVPF commentary
Dec 05, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MLYS is a Hold and NEVPF is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Dec 05, 2025
Stock price -- (MLYS: $39.20 vs. NEVPF: $0.03)
Brand notoriety: MLYS and NEVPF are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: MLYS: 152% vs. NEVPF: 100%
Market capitalization -- MLYS: $3.1B vs. NEVPF: $45.13M
MLYS [@Biotechnology] is valued at $3.1B. NEVPF’s [@Biotechnology] market capitalization is $45.13M. The market cap for tickers in the [@Biotechnology] industry ranges from $117.5B to $0. The average market capitalization across the [@Biotechnology] industry is $2.2B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

MLYS’s FA Score shows that 0 FA rating(s) are green whileNEVPF’s FA Score has 0 green FA rating(s).

  • MLYS’s FA Score: 0 green, 5 red.
  • NEVPF’s FA Score: 0 green, 5 red.
According to our system of comparison, MLYS is a better buy in the long-term than NEVPF.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

MLYS’s TA Score shows that 2 TA indicator(s) are bullish while NEVPF’s TA Score has 1 bullish TA indicator(s).

  • MLYS’s TA Score: 2 bullish, 6 bearish.
  • NEVPF’s TA Score: 1 bullish, 0 bearish.
According to our system of comparison, NEVPF is a better buy in the short-term than MLYS.

Price Growth

MLYS (@Biotechnology) experienced а -9.59% price change this week, while NEVPF (@Biotechnology) price change was 0.00% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.21%. For the same industry, the average monthly price growth was +5.86%, and the average quarterly price growth was +56.03%.

Industries' Descriptions

@Biotechnology (+1.21% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MLYS($3.1B) has a higher market cap than NEVPF($45.1M). MLYS YTD gains are higher at: 218.440 vs. NEVPF (-22.222). NEVPF has higher annual earnings (EBITDA): -87.99M vs. MLYS (-203.01M). MLYS has more cash in the bank: 325M vs. NEVPF (32.7M). MLYS (0) and NEVPF (0) have equivalent revenues.
MLYSNEVPFMLYS / NEVPF
Capitalization3.1B45.1M6,878%
EBITDA-203.01M-87.99M231%
Gain YTD218.440-22.222-983%
P/E RatioN/AN/A-
Revenue00-
Total Cash325M32.7M994%
Total DebtN/AN/A-
FUNDAMENTALS RATINGS
NEVPF: Fundamental Ratings
NEVPF
OUTLOOK RATING
1..100
43
VALUATION
overvalued / fair valued / undervalued
1..100
87
Overvalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
99
PRICE GROWTH RATING
1..100
40
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
9

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
MLYSNEVPF
RSI
ODDS (%)
Bearish Trend 2 days ago
87%
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
83%
N/A
Momentum
ODDS (%)
Bearish Trend 2 days ago
67%
N/A
MACD
ODDS (%)
Bearish Trend 2 days ago
70%
N/A
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
82%
Bullish Trend 2 days ago
13%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
83%
Bullish Trend 2 days ago
12%
Advances
ODDS (%)
Bullish Trend 23 days ago
88%
N/A
Declines
ODDS (%)
Bearish Trend 15 days ago
84%
N/A
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
N/A
Aroon
ODDS (%)
N/A
N/A
View a ticker or compare two or three
Interact to see
Advertisement
MLYS
Daily Signal:
Gain/Loss:
NEVPF
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
BRSVX39.680.64
+1.64%
Bridgeway Small-Cap Value
CCCNX6.590.07
+1.07%
Center Coast Brookfield Midstream Foc I
APHJX20.510.11
+0.54%
Artisan International Small-Mid Instl
NSIVX13.220.03
+0.23%
North Square Altrinsic Intl Eq I
JFRDX60.270.01
+0.02%
Janus Henderson Forty D

MLYS and

Correlation & Price change

A.I.dvisor indicates that over the last year, MLYS has been loosely correlated with CYTK. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if MLYS jumps, then CYTK could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MLYS
1D Price
Change %
MLYS100%
+0.13%
CYTK - MLYS
50%
Loosely correlated
+1.81%
IONS - MLYS
49%
Loosely correlated
+0.65%
NEVPF - MLYS
43%
Loosely correlated
N/A
PTGX - MLYS
38%
Loosely correlated
+1.68%
BIESF - MLYS
36%
Loosely correlated
N/A
More

NEVPF and

Correlation & Price change

A.I.dvisor indicates that over the last year, NEVPF has been closely correlated with MLTX. These tickers have moved in lockstep 70% of the time. This A.I.-generated data suggests there is a high statistical probability that if NEVPF jumps, then MLTX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NEVPF
1D Price
Change %
NEVPF100%
N/A
MLTX - NEVPF
70%
Closely correlated
+6.63%
IMA - NEVPF
66%
Loosely correlated
+6.76%
ATYR - NEVPF
65%
Loosely correlated
+9.27%
REPL - NEVPF
64%
Loosely correlated
+3.20%
SPRB - NEVPF
61%
Loosely correlated
+1.08%
More